Safety, Tolerability and Pharmacodynamics of SYNB1020

NCT03447730 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Interim futility analyses identified a lack of SYNB1020 efficacy.

Conditions

Cirrhosis

Interventions

DRUG: SYNB1020
OTHER: Placebo

Sponsor

Synlogic